Implanon® - The single-rod subdermal contraceptive implant

Journal of Drug Evaluation

Volumn 1, Issue 6, 2003, Pages 181-218

  Newton, John ^a   Newton, Patricia ^b  

^a BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

^b Family Planning   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANDROGEN RECEPTOR; ANTICONVULSIVE AGENT; CARBOHYDRATE; CONTRACEPTIVE AGENT; CTR 33; DESOGESTREL; ESTRADIOL; ESTROGEN; ETHYLENE VINYL ACETATE COPOLYMER; ETONOGESTREL; FOLLITROPIN; GESTAGEN; GESTODENE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVONORGESTREL; LIPID; LOCAL ANESTHETIC AGENT; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; NORETHISTERONE DERIVATIVE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; PROGESTERONE RECEPTOR; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ABDOMINAL PAIN; ACNE; AMENORRHEA; ASTHMA; BACKACHE; BILIARY TRACT DISEASE; BLEEDING DISORDER; BLOOD CLOTTING DISORDER; BONE DISEASE; BREAST FIBROADENOMA; BREAST TUMOR; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR DISEASE; CHOLELITHIASIS; CHRONIC TOXICITY; CLINICAL TRIAL; CYST; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSMENORRHEA; ENDOCRINE FUNCTION; ENDOMETRIUM ATROPHY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL DISEASE; GYNECOLOGIC DISEASE; HEADACHE; HEARING DISORDER; HEMOSTASIS; HUMAN; HYPERTENSION; IMPLANT; INJECTION PAIN; INSULIN RESISTANCE; INTRAUTERINE CONTRACEPTIVE DEVICE; LACTATION; LEUKORRHEA; LIBIDO DISORDER; LIPID METABOLISM; LIVER DISEASE; LIVER FUNCTION; MASTALGIA; MENSTRUAL CYCLE; MENSTRUATION DISORDER; MENTAL DISEASE; MENTAL INSTABILITY; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NAUSEA; NEOPLASM; NONHUMAN; NUTRITIONAL DISORDER; ORAL CONTRACEPTION; OVARY CYST; OVARY FUNCTION; OVULATION INHIBITION; PATIENT COUNSELING; PERIPHERAL NEUROPATHY; PHARYNGITIS; PREGNANCY; PROGESTERONE BLOOD LEVEL; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; SKIN APPENDAGE DISEASE; SPOTTING; SUSTAINED RELEASE FORMULATION; TACHYCARDIA; TERATOMA; THORAX PAIN; THROMBOCYTE DYSFUNCTION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT DISEASE; UTERUS MYOMA; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINITIS; VASCULAR DISEASE; VESTIBULAR DISORDER; VISUAL DISORDER; WEIGHT GAIN;

EID: 1542269321     PISSN: 14791137     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Segal SJ, Croxatto HB. Single administration of hormones for long-term control of reproductive function. Presented at the 23rd Meeting of the American Fertility Society Washington DC, 1967
2. Davies GC, Newton JR. Subdermal contraceptive implants - a review: with special reference to Norplant. Br J Fam Plann 1991;17:4-8
3. Darney PD, Atkinson E, Tanner S, et al. Acceptance and perceptions of Norplant among users in San Francisco, USA. Stud Fam Plann 1990a;21:152-60
4. Darney PD, Klaisle CM, Tanner S, et al. Sustained release contraceptives. Curr Prob Obstet Gynaecol Fertil 1990b; 13:87-125
5. Sivin I. International experience with Norplant and Norplant-2 contraceptives. Stud Fam Plann 1988;19:81-94
6. Affandi B, Santoso SS, Djajadilega, et al. Five-year experience with Norplant. Contraception 1987;36:417-28
7. Newton JR. Classification and comparison of oral contraceptives containing new generation progestogens. Hum Reprod Update 1995;1:231-63
8. San AP. Controlled-release devices: a status report. J Controlled Release 1992;22:35-46
9. Bergink EW, Hamburger AD, de Jager E, et al. Binding of a contraceptive progestogen ORG 2969 and its metabolites to receptor proteins and human sex hormone binding globulin. J Steroid Biochem 1981;14:175-83
10. Hoppen HO, Hammann P. The influence of structural modification on progesterone and androgen receptor binding of norethisterone. Correlation with nuclear magnetic resonance signals. Acta Endocrinol (Copenh) 1987;115:406-12
11. Bergink EW, van Meel F, Turpijn EW, et al. Binding of progestagens to receptors proteins in MCF-7 cells. J Steroid Biochem 1983;19:1563-70.
12. Kloosterboer HJ, Vonk-Noordegraaf CA, Turpijn EW. Selectivity in progesterones and androgen receptor binding of progestagens used in oral contraceptives. Contraception 1988;38:325-32
13. Scientific Development Group Release Report 4553. Oss, Netherlands; Organon, 1996
14. Scientific Development Group Release Report 836. Oss, Netherlands: Organon, 1978
15. Scientific Development Group Release Report 1743. Oss, Netherlands: Organon, 1985
16. van der Vies J, de Visser J. Endocrinological studies with desogestrel. Arzneimittelforschung 1983;33:231-6
17. Investigators' Brochure: Implanon. Oss, Netherlands: Organon, August 1998 (update)
18. Organon protocol reference 34504. Oss, Netherlands: Organon, 1998
19. Organon protocol reference 34507. Oss, Netherlands: Organon, 1998
20. Organon protocol reference 34508. Oss, Netherlands: Organon, 1998
21. Bennink HJ. The pharmacokinetics and pharmacodynamics of implanon, a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care 2000; 5(Suppl. 2):12-20
22. Affandi B, Suherman SK, Korver T, et al. A pharmacokinetic and pharmacodynamic study with a single implant containing 3-ketodesogestrel (Implanon). Med J Indonesia 1999;8:15-24
23. Wenzl R, van Beek A, Schnabel P, et al. Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon. Contraception 1998;58:283-8
24. Croxatto HB, Makarainen L. The pharmacodynamics and efficacy of Implanon. An overview of the data. Contraception 1998;58(Suppl. 6):91S-7S
25. Huber J, Wenzl R. Pharmacokinetics of Implanon. An integrated analysis. Contraception 1998;58(Suppl. 6):85S-90S
26. Diax S, Pavez M, Moo-Young AJ, et al. Clinical trial with 3-keto-desogestrel subdermal implants. Contraception 1991;44:393-408
27. Scientific Development Group Release Report 2904. Oss, Netherlands: Organon, 1998
28. Olsson SE, Odlind V, Johannson E. Clinical results with subcutaneous implants containing 3-keto desogestrel. Contraception 1990;42:1-11
29. Edwards JE, Moore A. Implanon. A review of clinical studies. Br J Fam Plann 1999;24(Suppl. 4):3-16
30. Affandi B, Hoesni HM, Barus RP, et al. A multicentred phase III comparative study between single-implant containing 3-ketodesogestrel (Implanon) and implants containing levonorgestrel (Norplant). II Vaginal bleeding patterns. Med J Indonesia 1999;8:56-81
31. Kiriwat O, Patanayindee A, Koetsawang A, et al. A 4-year pilot study on the efficacy and safety of Implanon, a single-rod hormonal contraceptive implant, in healthy women in Thailand. Eur J Contracept Reprod Health Care 1998; 3:85-91
32. Zheng SR, Zheng HM, Qian SZ, et al. A long-term study of the efficacy and acceptability of a single-rod hormonal contraceptive implant (Implanon) in healthy women in China. Eur J Contracep Reprod Health Care 1999;4:85-93
33. Zheng SR, Zheng HM, Qian SZ, et al. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and six-capsule (Norplant) hormonal contraceptive implant. Contraception 1999;60:1-8
34. Croxatto HB, Urbancsek J, Massai R, et al. A multi-centre efficacy and safety study of the single contraceptive implant, Implanon. Hum Reprod 1999;14:976-81
35. Croxatto HB. Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care 2000;5(Suppl. 5):21-8
36. Croxatto HB. Progestin implants. Steroids 2000;65:681-5
37. Huber J. Pharmacokinetics of Implanon, an integrated analysis. Contraception 1998;58(Suppl.):S85-91
38. Breiner M, Romalo G, Schweikert HU. Inhibition of androgen receptor binding by natural and synthetic steroids in cultured human genital skin fibroblasts. Klin Wochenschr 1986;64:732-7
39. Juchem M, Pollow K. Binding of oral contraceptive progestogens to serum proteins and cytoplasmic receptors. Am J Obstet Gynecol 1990;163:2171-83
40. Scientific Development Group Release Report 4513. Oss, Netherlands: Organon, 1998
41. Viinikka L, Ylikorkala O, Vikho R, et al. Metabolism of a new synthetic progestagen, Org 2969, in female volunteers. The distribution and excretion of radioactivity after an oral dose of the labelled drug. Acta Endocrinol (Copenh) 1980;93:375-9
42. Orme ML, Back DJ. Factors affecting the enterohepatic circulation of oral contraceptive steroids. Am J Obstet Gynecol 1990;163:2146-52
43. Beerthuizen R, van Beek A, Massai R, et al. Bone mineral density during long-term use of the progestogen contraceptive Implanon compared to a non-hormonal method of contraception. Hum Reprod 2000;15:118-22
44. Landgren BM, Diczfalusy E. Hormonal effects of the 300 mg norethisterone (NET) minipill, I. Daily steroid level in 43 subjects during a pretreatment cycle and during the second month of NET administration. Contraception 1980;21:87-113
45. Darney PD, Klaisle CM, Tanner S, et al. Sustained release contraceptives. Curr Probl Obstet Gynaecol Fertil 1990;13:87-96
46. Sivin I, Mishell ER Jr, Darney P, et al. Levonorgestrel capsule implants in the United States: a five year study. Obstet Gynaecol 1998;2:337-40
47. Makarainen L, van Beek A, Tuomivaara L, et al. Ovarian function during the use of a single contraceptive implant - Implanon compared with Norplant. Fertil Steril 1998;69:714-21
48. Bennink HJ. The pharmacokinetics and pharmacodynamics of Implanon - a single rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care 2000; 5(Suppl. 2):12-20
49. Newton JR. New methods of contraception. Bailliers Clin Obstet Gynecol 1996;10:87-101
50. Mascarenhas L, van Beek A, Bennink HC, et al. Twenty-four month comparison of apolipoproteins A-1, A-II and B in contraceptive implant users (Norplant and Implanon) in Birmingham, United Kingdom. Contraception 1998;58: 215-50
51. Makarainen L, van Beek A, Tuomivaara L, et al. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil Steril 1998;69:714-21
52. Implanon and You - Patient Questions Answered [booklet]. Oss, Netherlands: Organon, 1998:5-17
53. Implanon Investigator's Brochure (981106WB). Oss, Netherlands: Organon, 1998
54. Training Manual for Clinicians - Implanon. Oss, Netherlands: Organon, 1998
55. European Summary of Product Characteristics (SmPC). Oss, Netherlands: Organon, 2003
56. Edwards JE, Moore A. Implanon - a review of clinical studies. Br J Fam Plan 1999;22(Suppl.):3-16
57. Lantz A, Nosher JL, Pasquale S, et al. Ultrasound characteristics of subdermally implanted Implanon contraceptive rods. Contraception 1997;56:323-7
58. McCann MF, Potter LS. Progestin-only oral contraception: a comprehensive review. Contraception 1994;50(Suppl. 1): S1-198
59. Belsey EM, Farley TMM. The analysis of menstrual bleeding patterns: a review. Contraception 1988:38:129-56
60. Belsey EM, Machin D, d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research. Development and Research Training in Human Reproduction. Contraception 1986;34:253-60
61. Belsey EM, Pinol AP. Menstrual bleeding patterns in untreated women. Task Force on Long-Acting Systemic Agents for Fertility Regulation. Contraception 1997;55: 57-65
62. Urbancsek J. An integrated analysis of nonmenstrual adverse events with Implanon. Contraception 1998; 58(Suppl. 6):109S-15S
63. Egberg N, van Beek A, Gunnervik C, et al. Effects on the hemostatic system and liver function in relation to Implanon and Norplant. A prospective randomized clinical trial. Contraception 1998;58:93-8
64. Suherman SK, Affandi B, Korver T. The effects of Implanon on lipid metabolism in comparison with Norplant. Contraception 1999;60;281-7
65. Biswas A, Viegas OA, Coeling Bennink HJ, et al. Implanon contraceptive implants: effects on carbohydrate metabolism. Contraception 2001;63:137-41
66. Meirik O, Fraser IS, d'Arcangues C. Implantable contraceptives for women. Hum Reprod Update 2003;9:49-59
67. Konje JC, Otolorin EO, Ladipo OA. Changes in carbohydrate metabolism during 30 months on Norplant.
68. Shamma FN, Rossi G, HajHassan L, et al. The effect of Norplant of glucose metabolism under hyperglycemic hyperinsulinemic conditions. Fertil Steril 1995;63:767-72
69. Konje JC, Odukoya OA, Otolorin EO, et al. Carbohydrate metabolism before and after Norplant removal. Contraception 1992;46:61-9
70. Biswas A, Viegas OA, Bennink HJ, et al. Effects of Implanon use on selected parameters of thyroid and adrenal function. Contraception 2000;62:247-51
71. Scientific Development Group Release Report 4324. Oss, Netherlands: Organon, 1998
72. Atkinson HC, Begg EJ, Darlow BA. Drugs in human milk, clinical pharmacokinetic considerations. Clin Pharmaco kinetics 1988;14:217-40
73. World Health Organization Working Group. Guidelines for studies on the passage of drugs into breast milk. In Bennett PN, ed. Drugs and Lactation. Amsterdam: Elsevier, 1988:59-64
74. Bennett PN. A guide to the content and consequences of drugs, micronutrients, radiopharmaceuticals and environmental and occupational chemicals in human milk. Drugs and Lactation. Amsterdam: Elsevier, 1988: 160-79
75. Reinprayoon D, Taneepanichskul S, Bunyavejchevin S, et al. Effects of the etonogestrel-releasing contraceptive implant (Implanon) on parameters of breastfeeding compared to those of an intrauterine device. Contraception 2000;62:239-46